Allianz Asset Management’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.7M Sell
302,341
-576,917
-66% -$17.4M 0.01% 860
2026
Q2
$21M Buy
879,258
+67,934
+8% +$1.51M 0.02% 725
2026
Q1
$19.9M Buy
811,324
+189,025
+30% +$6.19M 0.02% 616
2025
Q4
$24.2M Sell
622,299
-26,052
-4% -$840K 0.02% 527
2025
Q3
$14.8M Sell
648,351
-65,391
-9% -$1.33M 0.02% 688
2025
Q2
$14.6M Buy
713,742
+74,265
+12% +$1.37M 0.02% 686
2025
Q1
$12.8M Buy
639,477
+317,103
+98% +$7.85M 0.02% 717
2024
Q4
$8.59M Buy
322,374
+251,821
+357% +$7.67M 0.01% 802
2024
Q3
$2.01M Buy
+70,553
New +$1.8M ﹤0.01% 1407
2020
Q2
– Sell
-29,319
Closed -$874K – 2416
2020
Q1
$874K Buy
+29,319
New +$885K ﹤0.01% 1851

Other funds holding CSTL

Allianz Asset Management's CSTL Position: Q3 2026 in Review

Allianz Asset Management reduced its Castle Biosciences (CSTL) stake by 66% in Q3 2026, selling an estimated $17.4M and leaving 302,341 shares worth $10.7M. The position accounts for 0.01% of the portfolio, ranked #860.

Allianz Asset Management first reported a position in CSTL in Q1 2020 and has held it in 10 quarters since. The position peaked at $24.2M in Q4 2025. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Allianz Asset Management held 302,341 shares of Castle Biosciences worth $10.7M as of Q3 2026.
  • Allianz Asset Management sold 576,917 Castle Biosciences shares in Q3 2026, an estimated $17.4M.
  • Castle Biosciences made up 0.01% of Allianz Asset Management's portfolio in Q3 2026, its #860 holding.
  • Allianz Asset Management first reported a position in Castle Biosciences in Q1 2020 and has held it in 10 quarters since.
  • Allianz Asset Management's Castle Biosciences position peaked at $24.2M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Allianz Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.